



HAL
open science

Aujeszky's disease (pseudorabies) virus: the virus and molecular pathogenesis - State of the art, June 1999

Thomas Mettenleiter

► To cite this version:

Thomas Mettenleiter. Aujeszky's disease (pseudorabies) virus: the virus and molecular pathogenesis - State of the art, June 1999. *Veterinary Research*, 2000, 31 (1), pp.99-115. 10.1051/vetres:2000059 . hal-00902643

HAL Id: hal-00902643

<https://hal.science/hal-00902643v1>

Submitted on 11 May 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Review article

Aujeszky's disease (pseudorabies) virus: the virus and molecular pathogenesis – State of the art, June 1999

Thomas C. METTENLEITER

Institute of Molecular Biology, Friedrich-Loeffler-Institutes,
Federal Research Centre for Virus Diseases of Animals, 17498 Insel Riems, Germany

Abstract – Considerable progress has been made during the last years in understanding the molecular basis of protein function in pseudorabies virus (PrV), the causative agent of Aujeszky's disease (AD). Major topics have been the identification and functional characterisation of viral envelope glycoproteins and cellular virus receptors, elucidation of viral proteins involved in neurovirulence and neuropathogenesis, detection and characterisation of attenuating mutations present in and leading to successful attenuated live vaccines, and the near completion of the genomic sequence of PrV DNA. This review, which follows an article prepared for the 1993 AD symposium in Budapest, Hungary, will briefly summarise those recent developments and update the reader on the current state of the art in PrV research.

Aujeszky's disease / pseudorabies virus / glycoprotein / molecular pathogenesis / tropism

Résumé – Le virus de la maladie d'Aujeszky : virus et pathogénèse au niveau moléculaire – État des lieux, Juin 1999. Ces dernières années ont donné lieu à des progrès considérables pour la compréhension des bases moléculaires de la fonction des protéines du virus de la maladie d'Aujeszky (VMA). Les principaux sujets d'étude ont été l'identification et la caractérisation fonctionnelle des glycoprotéines d'enveloppe et des récepteurs cellulaires pour le virus, la mise en évidence des protéines virales impliquées dans la neurovirulence et la neuropathogénèse, la détection et la caractérisation de mutations atténuantes présentes et pouvant conduire à des vaccins atténués efficaces, et l'achèvement presque total de la séquence génomique de l'ADN du virus. Cette revue de la littérature, qui fait suite à un article préparé pour le symposium de Budapest, Hongrie, sur la maladie d'Aujeszky (1993), va résumer ces développements récents, et faire une mise à jour, pour le lecteur, des recherches menées dans ce domaine.

maladie d'Aujeszky / pseudorabies virus / glycoprotéine / pathogénèse moléculaire

Table of contents

1. Introduction.....	100
2. Taxonomy.....	100
3. The virion.....	100
3.1. Genome.....	100
3.2. Capsid.....	102
3.3. Tegument.....	102
3.4. Envelope.....	102
4. The lytic replication cycle.....	105
4.1. Attachment and entry.....	105
4.2. Intranuclear events.....	107
4.3. Egress.....	108
5. Latency and neuroinvasion.....	108
6. Attenuation.....	109

1. INTRODUCTION

Since the last “state of the art” review [64], much time has passed. In the meantime, Aujeszky's disease (AD) and its causative agent, pseudorabies virus (PrV), have become “endangered” in several parts of the world. This result is mainly based on the successful development and use of marker vaccines which allow a serologic differentiation between infected and vaccinated animals. Several milestones have been set by PrV researchers: the very first official approval for use of a genetically engineered live vaccine [48], the development of the concept of marked vaccines [66,90], and the first approval for the use of a genetically engineered live vaccine in the European Community [79]. In this review, the major focus will be on PrV as a fascinating pathogen whose understanding at a molecular level has not only helped to combat and eventually hopefully eradicate the disease but has also greatly contributed to our understanding of alphaherpesvirus biology.

2. TAXONOMY

PrV belongs to the *Alphaherpesvirinae* subfamily of the *Herpesviridae*. It has been found, by comparison of deduced amino acid sequences of homologous proteins, to

be most closely related to bovine herpesvirus 1 (BHV-1) and equine herpesvirus 1 (EHV-1), and also to varicella-zoster virus (VZV) [59]. This prompted its assignment to the *Varicellovirus* genus within the Alphaherpesviruses. Alphaherpesviruses are distinguished by their rapid lytic growth in cell culture, their neurotropism, their latency in neurons and their broad host range. All these features are particularly pronounced in PrV and will be covered in this review. In spite of its broad host range which includes nearly all mammals except higher primates and humans, as well as other vertebrate species and cells in culture from various warm- and cold-blooded animals (Riebe et al., unpublished), the pig is the only host which is able to survive a productive infection and serve as a virus reservoir. This means that eliminating the virus from the porcine population can ultimately lead to eradication of the disease.

3. THE VIRION

Like all herpes virions, the PrV virion is composed of a nucleoprotein core which contains the genome, an icosahedral capsid of 162 capsomers, a proteinaceous tegument, and a lipid bilayer envelope derived from cellular membranes which contains virally encoded (glyco)proteins. Figure 1




Figure 1. Electron micrograph of a PrV virion attached to a bovine kidney cell (MDBK) in culture. Bar: 150nm. (Picture courtesy of Dr. Harald Granzow, Friedrich-Loeffler-Institutes, Insel Riems, Germany).

shows an electron micrograph of a PrV virion attached to a bovine kidney cell [36].

3.1. Genome

The genome of PrV consists of a double-stranded linear DNA of approximately 150 kbp. The complete sequence of the genomic DNA has not yet been determined, primarily because the high content of G+C nucleotides of 73% [6] renders sequencing laborious and costly. However, approximately 90% of the sequence has been elucidated and only one major gap in sequence information remains which, in analogy to other fully sequenced herpesvirus genomes and partial sequence information from PrV, probably contains the homologues of the UL31 to UL37 genes of herpes simplex virus 1 (HSV-1). A summary is shown in Figure 2. It should be noted that the

sequences are derived from several different PrV strains and mostly come in “bits and pieces”.

The genome consists of a long (U_L) and short unique region (U_S), the latter being bracketed by inverted repeats. So far, three origins of replication which conform to the alphaherpesvirus consensus sequence have been mapped in the repeats (2x) (Fuchs et al., unpublished) and middle of the unique long region [50]. Another replication origin with apparently unique features resides at the left end of the genome [55]. Interestingly, within the PrV genome an inversion of ca. 40 kbp is present which encompasses the UL27 to UL44 genes [6,9,25]. The biological significance of this genomic rearrangement is unclear. However, it is interesting that a similar inversion has also been detected in the only distantly related avian alphaherpesvirus infectious laryngotracheitis virus [99].




Figure 2. The PrV genome. In (A) the division of the genome into a unique long (U_L) and unique short (U_S) region by inverted repeats (open boxes) is shown. Arrows denote identified origins of replication. In (B) the Bam HI restriction fragment map of the PrV strain Ka is depicted. Those areas of the viral genome for which sequence information is available are designated in (C) by closed boxes. Shaded areas denote parts of the genome in which sequence information is present in the author's laboratory but not yet published. Only one gap remains, indicated by the hatched area, which contains the open reading frames homologous to the UL31 to UL37 genes of HSV.

A list of identified PrV genes and (partially putative) functions of the encoded proteins is shown in Table I. Approximately half of the alphaherpesvirus genes are considered as “nonessential”, that is they are dispensable for viral replication, at least in cell culture.

3.2. Capsid

Studies on capsid architecture have mainly been performed using HSV-1. However, the morphological similarity of herpesvirus capsids and the homology of capsid components indicates common principles. The alphaherpesvirus capsid is composed of products of the UL18 (part of “triplex” structures between capsomers), UL19 (major capsid protein which forms the hexon and penton capsomers), UL26 (scaffold, protease), UL26.5 (scaffold), UL35 (tips of hexons) and UL38 (triplex) genes [69]. The capsid is formed around a scaffolding structure which is proteolytically cleaved, and lost concomitant with incorporation of the genomic DNA into the

preformed capsid. In PrV, homologues to the UL18, UL19, UL26, UL26.5 and UL38 genes of HSV-1 have been detected. The UL35 gene most likely resides in the not yet sequenced region.

3.3. Tegument

Little is known about the composition and possible structure of the tegument. In electron micrographs it appears as an electron-dense amorphous structure which lies between capsid and envelope. Several proteins of HSV-1 have been identified as tegument components and homologues have also been found in PrV (see Tab. I).

3.4. Envelope

The PrV envelope is derived from intracellular membranes of vesicles in the *trans*-Golgi area [36,94]. The envelope contains virally encoded proteins, most of which are modified by addition of carbohydrate side chains and are, thus, designated as glyco-

Table I. PrV genes and proteins.

EHV-1 VZV		HSV-1	PrV	Function	Literature
1	–	–	ORF1		[5]
2	1	–	–		–
3	2	–	–		–
–	–	UL56	–	Virulence	–
4	3	UL55	–		–
5	4	UL54 (ICP27/IE63)	UL54	Gene regulation	[5]
6	5	UL53	UL53	gK	
7	6	UL52	UL52	Helicase/Primase	
8	7	UL51	UL51	Capsid/Tegument	
9	8	UL50	UL50	dUTPase	[40]
10	9A/8.5	UL49.5	UL49.5	gN	[41]
11	9	UL49 (VP22)	UL49	Tegument	Jöns et al., unpubl.
12	10	UL48 (VP16)	UL48	Tegument (Transact.)	
13	11	UL47 (VP13/14)	UL47	Tegument	[9]
14	12	UL46 (VP11/12)	UL46	Tegument	
15	–	UL45 (18K)	–	Membrane protein	
–	13	–	–	Thymidilate Synthase	
16	14	UL44	gIII	gC	[83]
17	15	UL43	UL43	Membrane protein	[76]
18	16	UL42	UL42	Polymerase assoc.	[8]
19	17	UL41	UL41	Host-cell shut-off	[7]
20	18	UL40	UL40	small RR	[23, 43]
21	19	UL39	UL39	large RR	
22	20	UL38 (VP19c)	UL38	Capsid	Kaliman et al., unpubl.
23	21	UL37	+	Tegument	Klupp et al., unpubl.
24	22	UL36 (ICP1/2)	+	Tegument	
25	23	UL35 (VP26)	+	Capsid	
26	24	UL34	+	Membrane protein	
27	25	UL33	+	Cleavage/Encapsid.	
28	26	UL32	+	Cleavage/Encapsid.	
29	27	UL31	+	Cleavage/Encapsid.	[37]
30	28	UL30	UL30	DNA-Polymerase	[8]
31	29	UL29 (ICP8)	UL29	DNA-binding	[95]
32	30	UL28 (ICP18.5)	ICP18.5	Cleavage/Encapsid.	[70]
33	31	UL27	gII	gB	[84]
34	32	–	–		
35	33	UL26 (VP24)	UL26	Protease	[11, 25]
35.5	33.5	UL26.5 (VP22a)	UL26.5	Scaffold	
36	34	UL25	UL25	Encapsidation	
37	35	UL24	UL24		
38	36	UL23	TK	Thymidine kinase	[47, 77]
39	37	UL22	gH	gH	[49]
40	38	UL21	UL21	Capsid protein	[24, 50]
41	39	UL20	UL20	Egress	
42	40	UL19 (VP5)	UL19	Major capsid protein	[50, 96]
43	41	UL18 (VP23)	UL18	Capsid	[50]
44/47	42/45	UL15.5	UL15	2 nd Exon	Dijkstra et al., unpubl.
45	43	UL17		Capsid Assembly	
46	44	UL16		Virion protein	
47	45	UL15		1 st Exon	
48	46	UL14	UL14		[22]
49	47	UL13 (VP18.8) UL12.5	UL13	Prot. Kin./TEG Nuclease	

Table I. *Continued.*

EHV-1 VZV		HSV-1	PrV	Function	Literature	
50	48	UL12	UL12	Alk. Nuclease	[38]	
51	49	UL11	UL11	Membrane protein		
52	50	UL10	UL10	gM	}	
		UL9.5	UL9.5			
53	51	UL9	UL9	Ori-binding		[29]
		UL8.5		Ori-binding	}	
54	52	UL8	UL8	Helicase/Primase		
55	53	UL7	UL7		}	
56	54	UL6	UL6	Capsid		[29, 71]
57	55	UL5	UL5	Helicase/Primase	}	
58	56	UL4	UL4			[20]
59	57		UL3.5	Egress	}	
60	58	UL3	UL3	Membrane?		[19]
61	59	UL2	UL2	Uracil-Glycosylase	}	
62	60	UL1	UL1	gL		[19, 51]
63	61	IE110 (ICP0)	EP0	Gene regulation		[15]
		γ34.5	-	Virulence	}	
64	62	IE175 (ICP4)	IE180	Gene regulation		[14]
65	63	US1 (IE68/ICP22)	RSp40	Gene regulation	[97]	
66	64	US10	-	Capsid/Tegument	}	
67	-	-	-			
68	-	US2	28K	Membrane protein	[91]	
69	66	US3	PK	Protein Kinase	[91, 98]	
70	-	US4	gX	gG	}	
71	-	-	-			[81]
		US5	-	gJ	}	
72	-	US6	gp50	gD		[75]
73	67	US7	gp63	gI	}	
74	68	US8	gI	gE		[73]
75	-	US8.5	-	Nucleoli-assoc.	}	
76	65	US9	11K	Membrane protein		[72]
-	-	US11	-	Nucleic acid binding	}	
-	-	US12 (IE12/ICP47)	-	TAP-blockade		

Genes in PrV are indicated compared to their counterparts in EHV-1, VZV and HSV-1. Designation of EHV-1 genes is according to [88], that of VZV genes is according to [18], that of HSV-1 genes according to [60,61]. PrV genes that have been completely sequenced are named as in their first description, mostly according to their HSV-1 counterparts. "+" indicates that partial sequence information is available. "-" indicates absence of gene. Information about function of the gene products in any of the viruses is also indicated.

proteins. In PrV, eleven glycoproteins have so far been described (Tab. II) which have been designated according to the unified nomenclature for herpesvirus glycoproteins as gB, gC, gD, gE, gG, gH, gI, gK, gL, gM, and gN. gB forms a homodimeric complex, and gE/gI, gH/gL, and gM/gN are present in heterooligomeric forms, presumably as heterodimers. All of these glycoproteins are constituents of the viral envelope except gG, which is abundantly produced during

PrV infection and released into the medium. Other putative nonglycosylated membrane proteins are the products of the UL3, UL11, UL20, UL34, and UL43 genes. Interestingly, the PrV genome does not contain a UL45 homologous gene, at least not at a colinear position, which specifies a membrane protein in HSV [17]. The Us9 protein of PrV has also recently been shown to represent a membrane protein [10].




Figure 3. The PrV replication cycle.

4. THE LYTIC REPLICATION CYCLE

A diagram depicting the different steps in the PrV replication cycle is shown in Figure 3.

4.1. Attachment and entry

Infection of cells by herpesviruses is initiated by attachment of free virions to target cells followed by fusion of the virion envelope and the cellular cytoplasmic membrane

Table II. Properties of pseudorabies virus glycoproteins.

Designation ^(a)	Gene ^(b)	Essential	Virion component	Attachment	Penetration	Cell-cell spread	Neuronal spread
gB (gII)	UL27	+	+	-	+ ^(c)	+	+
gC (gIII)	UL44	-	+	[+] ^(d)	-	-	-
gD (gp50)	US6	+	+	[+]	+	-	-
gE (gI)	US8	-	+	-	-	[+]	[+]
gG (gX)	US4	-	-	-	-	-	-
gH	UL22	+	+	-	+	+	+
gI (gp63)	US7	-	+	-	-	[+]	[+]
gK	UL53	+	+	-	-	+	? ^(e)
gL	UL1	+	+	-	+	+	?
gM	UL10	-	+	-	-	[+]	-
gN	UL49.5	-	+	-	[+]	-	-

(a) The old nomenclature of PrV glycoproteins has been added in parentheses.

(b) Gene designation according to the HSV-1 homologue.

(c) + indicates an essential function.

(d) [+] indicates a nonessential or modulating function.

(e) ?: no information available.

[63]. In both processes, the interaction between virion envelope glycoproteins and cellular surface components acting as virus receptors is critical. The first contact between PrV and the target cell is made by interaction of virion gC with heparan sulfate proteoglycans at the cell surface. This primary, relatively labile interaction converts into a stable binding which is mediated by interaction of gD with its cellular receptor [44]. Cellular alphaherpesvirus gD receptors have only recently been identified and proteins mediating PrV entry into otherwise relatively resistant chinese hamster ovary (CHO) cells belong to the poliovirus-receptor family [35, 93]. There may, however, be more receptors for PrV than those hitherto identified which is indicated by the fact that CHO cells are still infectable by PrV even in the absence of the gD receptors [69a] and that a gD-deficient mutant of PrV can infect cells via an alternate receptor [85]. Nevertheless, two viral glycoproteins, gC and gD, and two cellular groups of receptors, heparan sulfate proteoglycans and poliovirus-receptor related proteins, are involved in PrV attachment. Interestingly, gC is a nonessential protein, whereas gD is normally essential but can become dis-

pensable after selection in cell culture [85]. Recently, a PrV mutant has been selected which is infectious even in the absence of both attachment proteins, gC and gD [45], pointing to the presence of other yet unknown PrV attachment proteins.

For entry, the cellular cytoplasmic membrane and the viral envelope have to be in tight contact to fuse. For this fusion process to occur, at least four viral glycoproteins are required: gB, gH/gL, and gD [63]. Absence of either of these glycoproteins in engineered viral mutants renders these viruses incapable to fuse. The molecular mechanisms by which these proteins mediate fusion are, however, still unclear. It is interesting, though, that at least the most highly conserved gB glycoproteins show partial cross complementation between different alphaherpesviruses which is indicative of a common mechanism of membrane fusion at least in this subfamily [80]. It should also be noted that gB, gH, and gL belong to those viral proteins whose genes are conserved throughout the herpesvirus family.

After translocation of the nucleocapsid into the cytoplasm of the cell, it is transported to the nuclear membrane and locates

adjacent to nuclear pores. This transport most likely occurs along microtubules [36, 87]. The capsid is invariably oriented towards the nuclear pore so that one vertex is juxtaposed to the pore complex (Fig. 3) [36]. The DNA presumably leaves the virion and enters the nucleus through this vertex.

4.2. Intranuclear events

The incoming linear DNA circularises and transcription starts in the nucleus. Herpesvirus transcription is regulated in a cascade-like fashion. First, immediate-early (ie) genes which encode regulatory proteins are expressed. Unlike most other herpesviruses, PrV contains only one gene which is expressed with immediate-early kinetics. This gene encodes IE180 which is homologous to the major immediate-early protein of HSV-1, ICP4 [14]. PrV homologues to other HSV-1 ie-genes are present in PrV such as EP0 (ICP0 in HSV), RSp40 (ICP22 in HSV) and UL54 (ICP27 in HSV). These PrV genes are, however, regulated as early (e) genes. No PrV homologue to the ICP47 ie-protein of HSV-1 has been detected.

IE180 is a potent transactivator of early genes which include those encoding proteins required for DNA replication and other enzymatic functions. Early genes are characterised as being expressed before DNA replication. PrV encodes a number of proteins with enzymatic activity (see Tab. I). The most notable is thymidine kinase, an enzyme which is nonessential for viral growth in tissue culture but required for neurovirulence [48,62; see also below], as are dUTPase [42] and ribonucleotide reductase [23].

Replication of the viral genome requires the presence of the products of the UL5 (helicase), UL8 (helicase/primase), UL9 (origin of replication-binding protein), UL29 (major DNA binding protein), UL30 (DNA-polymerase), UL42 (polymerase-associated protein) and UL52 (primase) genes [8]. They

are needed for recognition of the site for initiation of DNA synthesis, for unwinding the supercoiled DNA, melting the double-helix, and synthesis of the complementary leading and lagging strands. Herpesvirus DNA replication proceeds by a rolling-circle mechanism leading to long head-to-tail concatemeric DNA molecules which need to be cleaved into unique length genomes before or during packaging into capsids. A large proportion of intranuclear viral DNA is present in those high molecular weight concatemeric structures.

Lastly, late genes specify several capsid and envelope components, for example gC. It must be stressed, however, that the differentiation into these three kinetic classes is not absolute and several exceptions have been described (for example, a number of early-late genes whose expression starts before DNA replication but which reach their maximum expression levels only after DNA replication has begun).

After synthesis in the cytoplasm, capsid proteins enter the nucleus and form the basis for capsid assembly. This process is autocatalytic and requires only the respective capsid components [69]. In electron micrographs, intranuclear crescent shaped capsids can be observed indicating a step-by-step addition of capsomers to the nascent capsid precursor [36]. Intranuclear capsids are observed in three forms: with an inner scaffold structure, without a scaffold and with DNA, and without a scaffold and without DNA [67]. The latter are presumably the result of abortive DNA encapsidation attempts and are dead-end products. The products of the UL6, UL15, UL17, UL25, UL28, UL31, UL32 and UL33 genes [56] are involved in cleavage-encapsidation of concatemeric HSV-1 DNA. The UL28 gene product has also been described to be essential for capsid maturation in PrV [67].

4.3. Egress

Full capsids leave the nucleus by budding through the inner nuclear membrane. This first viral envelope appears “smooth” under the electron microscope which indicates the absence of (mature) glycoproteins. Also, virions in the perinuclear space lack or contain only very little tegument [36]. Virions leave the perinuclear space by fusion of the primary envelope with the outer nuclear membrane resulting in the release of naked capsids into the cytoplasm. A secondary envelopment process then takes place in the *trans*-Golgi area in which capsids bud into lamellae and vesicles of the *trans*-Golgi [36, 94]. Now, tegument is included and the secondary envelope clearly contains spike projections consisting of viral glycoproteins. The PrV UL3.5 gene product is essential for this process [33]. The net result of this budding event is the presence of a complete virus particle within a vesicle. These vesicles then move to the cytoplasmic membrane (a process which is blocked in the absence of the UL20 gene product) [34], fuse with the cytoplasmic membrane, and release the virus particle into the extracellular space. It is puzzling why released virions do not immediately re-enter the cell they have just left. Our data indicate that gK plays an important role in inhibition of re-fusion [53].

5. LATENCY AND NEUROINVASION

Despite intensive efforts, the molecular basis for alphaherpesvirus latency is still largely unknown. In PrV, latently infected pigs are a constant danger for reactivation and virus shedding and thus for spreading of the virus in a susceptible population. Latency is defined as a status in which viral DNA persists but infectious virus is not produced. It is now common knowledge that during latency, viral gene expression is restricted to transcription of a distinct part of

the viral genome into the so-called latency associated transcripts or LATs [78]. In HSV, these LATs exhibit antisense orientation to the mRNA for the regulatory immediate-early protein, ICP0. LAT expression in HSV is, however, not required for establishment of latency but may under certain circumstances play a role in reactivation.

A spliced and polyadenylated RNA, designated as the large latency transcript of 8.5 kb, is expressed during PrV latency under control of a specific promoter, antiparallel to the IE180 and EP0 genes [15]. Whether this mRNA encodes any functional protein is unclear at present (reviewed in [30]).

Major sites of PrV latency are the trigeminal ganglion (TG), the olfactory bulb, and the tonsil. In these organs, viral DNA can be detected in the absence of infectious virus production, and LAT transcription could also be demonstrated by highly sensitive methods such as RT-PCR [16]. Presumably, after oronasal infection, PrV first replicates in the epithelial tissues and may also directly enter nerve endings of sensory neurons in the nasopharynx. After a first round of replication in the epithelia, progeny virus is abundantly produced leading to an increased infection of primary neurons.

Interestingly, there appears to be a correlation between precolonisation of trigeminal ganglia with PrV and failure of a superinfecting strain to become latent itself. This indicates that the number of neurons in which latency will be established is limited and that, probably, an already “occupied” neuron resists superinfection. Whether this interference requires a viral function or is dependent on cellular factors is unknown. It may, however, be deduced that attenuated live vaccine strains with a high potential for establishment of latency may prevent superinfecting wildtype strains from becoming latent [86].

Recently, the proteins which are required for neuroinvasion of PrV were analysed in detail. Several studies in mice, rats, and pigs

have indicated that one of the key proteins in neuroinvasion is glycoprotein E [2, 3, 12, 13, 31]. Deletion of this protein strongly attenuates PrV (see also below). Absence of gE does not impair primary viral replication in the nasal epithelium after intranasal infection of mice or pigs [2, 3, 54]. It is also not required for the virus to enter primary neurons. Transsynaptic transfer to second order neurons is, however, severely inhibited, resulting in a dramatic restriction in neuroinvasion. gE, and to a lesser extent gI, are the predominant nonessential glycoproteins exhibiting this dramatic phenotype [32]. Other proteins which are required for cell-to-cell spread in culture are also essential for neuronal spread in the animal. These include gB and gH [1]. As in cell culture, gD is not required for transsynaptic transfer but is essential for entry into primary target cells. Thus, phenotypically gD-complemented gD⁻ PrV invades the central nervous system after primary replication, and is virulent in mice [1].

The specific transneuronal transmission properties of PrV have sparked neuroanatomists to use this virus for tracing interconnecting neuronal circuits [32, 57, 89]. Several PrV mutants lacking gE which exhibit a restricted propagation in the CNS have thus been used. Visualisation of cells infected by mutant PrV has been facilitated by the insertion of marker genes expressing easily identifiable proteins such as β -galactosidase or green fluorescent protein [65]. Most notably, tracing studies using pairs of genetically and phenotypically differentiable PrV mutants have allowed simultaneous tracing of different neuronal pathways [39].

6. ATTENUATION

The obvious success of the AD eradication programs is primarily based on the efficacy and safety of the modified live vaccines used. For containment of AD and suppression of symptoms, live vaccines,

which had been attenuated by classical means such as extensive passaging in vitro or selection for drug-resistance or temperature-sensitivity, have been used for a long time. One of these strains is represented by the vaccine strain Bartha, now a "classic" within the PrV vaccine repertoire [4].

Molecular analysis of this strain for more than 15 years finally led to the identification of the genomic mutations responsible for attenuation. PrV Bartha contains a large deletion within the U_S region of the viral genome which encompasses part of the gI, all of the gE and Us9, and part of the Us2 genes [58,74]. It also carries mutations within the gC gene which include an alteration in the aminoterminal signal sequence resulting in inefficient intracellular translocation and incorporation of this protein into the viral envelope [82]. Lastly, point mutations within the UL21 gene, whose product is involved in capsid formation, contribute to the avirulence of PrV Bartha [52]. Restoration of all three defects is required for recovery of the virulent phenotype. Thus, PrV Bartha harbours three independent attenuating defects which explain its high safety (Fig. 4). Moreover, PrV Bartha is interesting in that it expresses an additional modified protein. The product of the UL10 gene is a protein conserved throughout the herpesviruses and its product has been identified as a nonessential glycoprotein, gM. Surprisingly, the Bartha UL10 gene contains mutations which abolish the single N-glycosylation site for the protein so that Bartha's UL10 product is not glycosylated and, thus, cannot be named "g"^M [26,27]. However, this mutation apparently does not influence virulence of this strain.

During the strive for combatting AD, genetic engineering methods were first used to develop attenuated strains by inactivating the gene encoding the thymidine kinase (TK) enzyme. In fact, one of these TK-negative strains became the very first genetically modified live vaccine licensed for use [47, 48]. Another milestone was the licensing of a similar genetically modified strain

Mutations in PrV vaccine strain Bartha




Figure 4. Mutations present in the genome of the PrV strain Bartha. The deletion in the U_S region encompassing the gI, gE, Us9 and Us2 genes, and the mutations in the gC, UL10, and UL21 genes are indicated. The consequences of these mutations on the envelope structure of PrV Bartha are depicted schematically below in comparison with PrV wildtype (WT).

for use in western Europe [79]. As mentioned above, PrV Bartha naturally lacks gE which was first demonstrated by Mettenleiter et al. [66]. Based on this finding, van Oirschot et al. [90] developed a serological test which is able to distinguish between animals which carry antibodies against gE (after a field virus infection) and those which lack antibodies against gE but carry antibodies against other PrV glycoproteins (after vaccination). Thus the concept of the “marked” vaccine emerged. The success of the AD eradication programs based on these marked vaccines testifies for the applicability of this concept. In the

meantime, deletions of the gE- but also of the gC- and gG-genes which can also be used as markers, have been primarily introduced by genetic engineering methods. PrV therefore serves as an excellent example of how molecular biology and basic science profoundly influence practical animal disease control.

Besides TK, RR, and gE [23, 46, 48, 68], inactivation of several other PrV genes has been shown to result in attenuation of the virus. In fact, inactivation of most genes whose products are nonessential for viral replication in cell culture somehow

Table III. Virulence-modulating nonessential genes and proteins of PrV.

<i>Gene</i>	<i>Protein</i>	<i>Category</i>
UL10	Glycoprotein gM	Envelope Glycoprotein
UL13	Protein kinase	Enzyme
UL21		Capsid Protein
UL23	Thymidine kinase	Enzyme
UL39/40	Ribonucleotide Reductase	Enzyme
UL44	Glycoprotein gC	Envelope Glycoprotein
UL50	dUTPase	Enzyme
US3	Protein kinase	Enzyme
US7	Glycoprotein gI	Envelope Glycoprotein
US8	Glycoprotein gE	Envelope Glycoprotein

decreases PrV virulence. A list of published examples is shown in Table III. It can be concluded that nowadays with genetic engineering techniques, a number of possible target genes are accessible for the construction of viruses with different attenuated properties [21, 28, 42, 48].

Lastly, PrV has been developed into a powerful vector system for expression of heterologous genes. Although none of these vectors has so far attained the status of practical application, PrV-classical swine fever recombinants [92] may indeed help fight two devastating pig diseases at the same time with a vaccine which has the benefit of being "marked" for AD (by the absence of gE) and classical swine fever (by the sole presence of CSFV-E2). For insertion of foreign genes, numerous insertion sites have been described which may also be used for integration of several different heterologous genes.

ACKNOWLEDGMENTS

Work in the author's laboratory has been supported by the Deutsche Forschungsgemeinschaft, the European Union, and Intervet International B.V. I thank Barbara Klupp, Klaus Osterrieder and Ines Jakobi for help in preparing this manuscript, and Jerg Schmidt for the artwork.

REFERENCES

- [1] Babic N., Mettenleiter Th.C., Flamand A., Ugolini G., Role of essential glycoproteins gII and gp50 in transneuronal transfer of pseudorabies virus from the hypoglossal nerves of mice, *J. Virol.* 67 (1993) 4421-4426.
- [2] Babic N., Mettenleiter Th.C., Ugolini G., Flamand A., Coulon P., Propagation of pseudorabies virus in the nervous system of the mouse after intranasal inoculation, *Virology* 204 (1994) 616-625.
- [3] Babic N., Klupp B.G., Brack A., Mettenleiter Th.C., Flamand A., Deletion of glycoprotein gE reduces the propagation of pseudorabies virus in the nervous system of the mouse after intranasal inoculation, *Virology* 219 (1996) 279-284.
- [4] Bartha A., Experimental reduction of virulence of Aujeszky's disease virus (in Hungarian), *Magyar Allatorvosok Lapja* 16 (1961) 42-45.
- [5] Baumeister J., Klupp B.G., Mettenleiter Th.C., Pseudorabies virus and equine herpesvirus 1 share a nonessential gene which is absent in other herpesviruses and located adjacent to a highly conserved gene cluster, *J. Virol.* 69 (1995) 5560-5567.
- [6] Ben-Porat T., Kaplan A.S., Molecular biology of pseudorabies virus, in: Roizman B. (Eds.), *The Herpesviruses*, Plenum Press, New York, 1985, pp. 105-173.
- [7] Berthomme H., Jacquemont B., Epstein A., The pseudorabies virus host-shutoff homolog gene: nucleotide sequence and comparison with alpha-herpesvirus protein counterparts, *Virology* 193 (1993) 1028-1032.
- [8] Berthomme H., Monahan S.J., Parris D.S., Jacquemont B., Epstein A.L., Cloning, sequencing, and functional characterization of the two subunits of the pseudorabies virus DNA polymerase holoenzyme: evidence for specificity of interaction, *J. Virol.* 69 (1995) 2811-2818.

- [9] Bras F., Dezélee S., Simonet B., Nguyen X., Vende P., Flamand A., Masse M.J., The left border of the genomic inversion of pseudorabies virus contains genes homologous to the UL46 and UL47 genes of herpes simplex virus type 1, but no UL45 gene, *Virus Res.* 60 (1999) 29-40.
- [10] Brideau A.D., Banfield B.W., Enquist L.W., The US9 gene product of pseudorabies virus, an alpha-herpesvirus, is a phosphorylated, tail-anchored type II membrane protein, *J. Virol.* 72 (1998) 4560-4570.
- [11] Camacho A., Tabarés E., Characterization of the genes, including that encoding the viral proteinase, contained in *Bam*HI restriction fragment 9 of the pseudorabies virus genome, *J. Gen. Virol.* 77 (1996) 1865-1874.
- [12] Card J.P., Pseudorabies virus replication and assembly in the rodent central nervous system, in: Kaplitt M., Loewy A.D. (Eds.), *Viral Vectors*, Academic Press, Inc., 1995, pp. 319-347.
- [13] Card J.P., Levitt P., Enquist L.W., Different patterns of neuronal infection after intracerebral injection of two strains of pseudorabies virus, *J. Virol.* 72 (1998) 4434-4441.
- [14] Cheung A.K., DNA nucleotide sequence analysis of the immediate-early gene of pseudorabies virus, *Nucl. Acids Res.* 17 (1989) 4637-4646.
- [15] Cheung A.K., Cloning of the latency gene and the early protein 0 gene of pseudorabies virus, *J. Virol.* 65 (1991) 5260-5271.
- [16] Cheung A.K., Investigation of pseudorabies virus DNA and RNA in trigeminal ganglia and tonsil tissues of latently infected swine, *Am. J. Vet. Res.* 56 (1995) 45-50.
- [17] Cockrell A.S., Muggeridge M.I., Herpes simplex virus 2 UL45 is a type II membrane protein, *J. Virol.* 72 (1998) 4430-4433.
- [18] Davison A.J., Scott J.E., The complete DNA sequence of varicella-zoster virus, *J. Gen. Virol.* 67 (1986) 1759-1816.
- [19] Dean H.J., Cheung A.K., A 3' coterminal gene cluster in pseudorabies virus contains herpes simplex virus UL1, UL2, and UL3 gene homologs and a unique UL3.5 open reading frame, *J. Virol.* 67 (1993) 5955-5961.
- [20] Dean H.J., Cheung A.K., Identification of the pseudorabies virus UL4 and UL5 (helicase) genes, *Virology* 202 (1994) 962-967.
- [21] Dean H.J., Cheung A.K., A deletion at the U_L/U_R junction reduces pseudorabies virus neurovirulence, *J. Virol.* 69 (1995) 1334-1338.
- [22] DeWind N., Domen J., Berns A., Herpesviruses encode an unusual protein-serine/threonine kinase which is nonessential for growth in cultured cells, *J. Virol.* 66 (1992) 5200-5209.
- [23] DeWind N., Berns A., Gielkens A., Kimman T., Ribonucleotide reductase-deficient mutants of pseudorabies virus are avirulent for pigs and induce partial protective immunity, *J. Gen. Virol.* 74 (1993) 351-359.
- [24] De Wind N., Wagenaar F., Pol J., Kimman T., Berns A., The pseudorabies virus homolog of the herpes simplex virus UL21 gene product is a capsid protein which is involved in capsid maturation, *J. Virol.* 66 (1992) 7096-7103.
- [25] Dezélee S., Bras F., Vende P., Simonet B., Nguyen X., Flamand A., Masse M.J., The *Bam*HI fragment 9 of pseudorabies virus contains genes homologous to the UL24, UL25, UL26, and UL26.5 genes of herpes simplex virus 1, *Virus Res.* 42 (1996) 27-39.
- [26] Dijkstra J., Mettenleiter Th.C., Klupp B.G., Intracellular processing of pseudorabies virus glycoprotein M (gM): gM of strain Bartha lacks N-glycosylation, *Virology* 237 (1997) 113-122.
- [27] Dijkstra J., Visser N., Mettenleiter Th.C., Klupp B.G., Identification and characterization of pseudorabies virus glycoprotein gM as a nonessential virion component, *J. Virol.* 70 (1996) 5684-5688.
- [28] Dijkstra J., Gerdts V., Klupp B.G., Mettenleiter Th.C., Deletion of glycoprotein gM of pseudorabies virus results in attenuation for the natural host, *J. Gen. Virol.* 78 (1997) 2147-2151.
- [29] Dijkstra J.M., Fuchs W., Mettenleiter T.C., Klupp B.G., Identification and transcriptional analysis of pseudorabies virus UL6 to UL12 genes, *Arch. Virol.* 142 (1997) 17-35.
- [30] Enquist L.W., Infection of the mammalian nervous system by pseudorabies virus (PRV), *Seminars in Virol.* 5 (1994) 221-231.
- [31] Enquist L.W., Circuit-specific infection of the mammalian nervous system, *ASM News* 61 (1995) 633-638.
- [32] Enquist L.W., Husak P.J., Banfield B.W., Smith G.A., Infection and spread of alphaherpesviruses in the nervous system, *Advances in Virus Res.* 51 (1999) 237-347.
- [33] Fuchs W., Klupp B.G., Rziha H.-J., Mettenleiter Th.C., Identification and characterization of the pseudorabies virus UL3.5 protein, which is involved in virus egress, *J. Virol.* 70 (1996) 3517-3527.
- [34] Fuchs W., Klupp B.G., Granzow H., Mettenleiter Th.C., The UL20 gene product of pseudorabies virus functions in virus egress, *J. Virol.* 71 (1997) 5639-5646.
- [35] Geraghty R.J., Krummenacher C., Cohen G.H., Eisenberg R.J., Spear P.G., Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor, *Science* 280 (1998) 1618-1620.
- [36] Granzow H., Weiland F., Jöns A., Klupp B., Karger A., Mettenleiter Th.C., Ultrastructural Analysis of the Replication Cycle of Pseudorabies Virus in Cell Culture: A Reassessment, *J. Virol.* 71 (1997) 2072-2082.
- [37] Ho T.-Y., Hsiang C.-Y., Chang T.-J., Analysis of pseudorabies virus genes by cDNA sequencing, *Gene* 175 (1996) 247-251.

- [38] Hsiang C.-Y., Ho T.Y., Chang T.-J., Identification of a pseudorabies virus UL12 (deoxyribonuclease) gene, *Gene* 177 (1996) 109-113.
- [39] Jansen A., van Nguyen X., Karpitskiy V., Mettenleiter Th.C., Loewy A., Central command neurons of the sympathetic nervous system - neuroanatomical basis of the fight-or-flight response, *Science*, 270 (1995) 644-646.
- [40] Jöns A., Mettenleiter Th.C., Identification and characterization of pseudorabies virus dUTPase, *J. Virol.* 70 (1996) 1242-1245.
- [41] Jöns A., Granzow H., Kuchling R., Mettenleiter Th.C., The UL49.5 gene of pseudorabies virus (PrV) codes for an O-glycosylated structural protein of the viral envelope, *J. Virol.* 70 (1996) 1237-1241.
- [42] Jöns A., Gerdt V., Lange E., Kaden V., Mettenleiter Th.C., Attenuation of dUTPase deficient pseudorabies virus for the natural host, *Vet. Microbiol.* 56 (1997) 47-54.
- [43] Kaliman A.V., Boldogkői Z., Fodor I., Large and small subunits of the Aujeszky's disease virus ribonucleotide reductase: nucleotide sequence and putative structure, *Biochim. Biophys. Acta* 1219 (1994) 151-156.
- [44] Karger A., Mettenleiter Th.C., Glycoproteins gIII and gp50 play dominant roles in the biphasic attachment of pseudorabies virus, 194 (1993) 654-664.
- [45] Karger A., Schmidt J., Mettenleiter Th.C., Infectivity of a pseudorabies virus mutant lacking attachment glycoproteins C and D, *J. Virol.* 72 (1998) 7314-7348.
- [46] Kimman T., de Wind N., Oei-Lie N., Pol J., Berns A., Gielkens A., Contribution of single genes within the unique short region of Aujeszky's disease virus (suid herpesvirus type 1) to virulence, pathogenesis and immunogenicity, *J. Gen. Virol.* 73 (1992) 243-251.
- [47] Kit S., U.S. Patent Application no. 4514497, 1985.
- [48] Kit S., Kit M., Bartkoski M.J., Dees G., Genetically engineered pseudorabies virus vaccine with deletions in thymidine kinase and glycoprotein genes, *Cold Spring Harbor Symposium Vaccines* 87: Pseudorabies Vaccines (1987) 345-349.
- [49] Klupp B., Mettenleiter Th.C., Sequence and expression of the glycoprotein gH gene of pseudorabies virus, *Virology* 182 (1991) 732-741.
- [50] Klupp B., Kern H., Mettenleiter Th.C., The virulence-determining genomic Bam HI-fragment 4 of pseudorabies virus contains genes corresponding to the UL15 (partial), UL18, UL19, UL20, and UL21 genes of herpes simplex virus and a putative origin of replication, *Virology* 191 (1992) 900-908.
- [51] Klupp B.G., Baumeister J., Karger A., Visser N., Mettenleiter Th.C., Identification and characterization of a novel structural glycoprotein in pseudorabies virus, gL, *J. Virol.* 68 (1994) 3868-3878.
- [52] Klupp B.G., Lomniczi B., Visser N., Fuchs W., Mettenleiter Th.C., Mutations affecting the UL21 gene contribute to avirulence of pseudorabies virus vaccine strain Bartha, *Virology* 212 (1995) 466-473.
- [53] Klupp B., Baumeister J., Dietz P., Granzow H., Mettenleiter Th.C., Pseudorabies virus glycoprotein gK is a structural component of virions involved in virus release but not required for entry, *J. Virol.* 72 (1998) 1949-1958.
- [54] Kritas S.K., Pensaert M., Mettenleiter Th.C., Invasion and spread of single glycoprotein deleted mutants of Aujeszky's disease virus (ADV) in the trigeminal nervous pathway of pigs after intranasal inoculation, *Vet. Microbiol.* 40 (1994) 323-334.
- [55] Kupersmidt S., de Marchi J., Lu Z., Ben-Porat T., Analysis of an origin of DNA replication located at the L terminus of the genome of pseudorabies virus, *J. Virol.* 65 (1991) 6283-6291.
- [56] Lamberti C., Weller S.K., The herpes simplex virus type 1 cleavage/packaging protein, UL32, is involved in efficient localization of capsids to replication compartments, *J. Virol.* 72 (1998) 2463-2473.
- [57] Loewy A.D., Pseudorabies virus: a transneuronal tracer for neuroanatomical studies, in: Kaplitt M., Loewy A.D. (Eds.), *Viral Vectors*, Academic Press, Inc., 1995, pp. 349-366.
- [58] Lomniczi B., Watanabe S., Ben-Porat T., Kaplan A.S., Genetic basis of the neurovirulence of pseudorabies virus, *J. Virol.* 52 (1984) 198-205.
- [59] McGeoch D.J., Cook S., Molecular phylogeny of the *alpha*herpesvirinae subfamily and a proposed evolutionary timescale, *J. Mol. Biol.* 238 (1994) 9-22.
- [60] McGeoch D.J., Dolan A., Donald S., Rixon F.J., Sequence determination and genetic content of the short unique region of the genome of herpes simplex virus type 1, *J. Molec. Biol.* 181 (1985) 1-13.
- [61] McGeoch D.J., Dalrymple M.A., Davison A.J., Dolan A., Frame M.C., McNab D., Perry L.J., Scott J.E., Taylor P., The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1, *J. Gen. Virol.* 69 (1988) 1531-1574.
- [62] McGregor S., Easterday B.C., Kaplan A.S., Ben-Porat T., Vaccination of swine with thymidine kinase-deficient mutants of pseudorabies virus, *Am. J. Vet. Res.* 46 (1985) 1494-1497.
- [63] Mettenleiter Th.C., Initiation and spread of α -Herpesvirus infections, *Trends Microbiol.* 2 (1994) 2-4.
- [64] Mettenleiter Th.C., Pseudorabies (Aujeszky's disease) virus: State of the art, August 1993, *Acta Vet. Hung.* 42 (1994) 153-177.
- [65] Mettenleiter Th.C., Molecular properties of alpha-herpesviruses used in neuronal pathway tracing, in: Kaplitt M., Loewy A.D. (Eds.), *Viral Vectors*, Academic Press, Inc., 1995, pp. 367-393.

- [66] Mettenleiter Th.C., Lukacs N., Rziha H.-J., Pseudorabies virus avirulent strains fail to express a major glycoprotein, *J. Virol.* 56 (1985) 307-311.
- [67] Mettenleiter Th.C., Saalmüller A., Weiland F., Pseudorabies virus protein homologous to herpes simplex virus type 1 ICP18.5 is necessary for capsid maturation, *J. Virol.* 67 (1993) 1236-1245.
- [68] Mettenleiter Th.C., Zsak L., Kaplan A, Ben-Porat T., Lomniczi B., Role of a structural glycoprotein of pseudorabies in virus virulence, *J. Virol.* 61 (1987) 4030-4032.
- [69] Newcomb W.N., Homa F.L., Thomsen D.R., Trus B.L., Cheng N., Steven A., Booy F., Brown J.C., Assembly of the herpes simplex virus procapsid from purified components and identification of small complexes containing the major capsid and scaffolding proteins, *J. Virol.* 73 (1999) 4239-4250.
- [69a] Nixdorf R., Schmidt J., Karger A., Mettenleiter T.C., Infection of chinese hamster ovary cells by pseudorabies virus, *J. Virol.* 73 (1999) 8019-8026.
- [70] Pedersen N., Enquist L., The nucleotide sequence of a pseudorabies virus gene similar to ICP18.5 of herpes simplex virus type 1, *Nucleic Acids Res.* 17 (1989) 3597.
- [71] Pedersen N.E., Casey II J.T., Koslowski K.M., Shaver P.R., The UL6 locus of pseudorabies virus and its homology to oncogenic herpesviruses, *Oncol. Rep.* 5 (1998) 115-119.
- [72] Petrovskis E., Post L., A small open reading frame in pseudorabies virus and implications for evolutionary relationships between herpesviruses, *Virology* 159 (1987) 193-195.
- [73] Petrovskis E., Timmins J.G., Post L., Use of λ gt11 to isolate genes for two pseudorabies virus glycoproteins with homology to herpes simplex virus and varicella-zoster virus glycoproteins, *J. Virol.* 60 (1986) 185-193.
- [74] Petrovskis E.A., Timmins J.G., Gierman T.M., Post L.E., Deletions in vaccine strains of pseudorabies virus and their effect on synthesis of glycoprotein gp63, *J. Virol.* 60 (1986) 1166-1169.
- [75] Petrovskis E., Timmins J.G., Armentrout M.A., Marchioli C.C., Yancy R.J., Post L.E., DNA sequence of the gene for pseudorabies virus gp50, a glycoprotein without N-linked glycosylation, *J. Virol.* 59 (1986) 216-223.
- [76] Powers L., Wilkinson K.S., Ryan P., Characterization of the prv43 gene of pseudorabies virus and demonstration that it is not required for virus growth in cell culture, *Virology* 199 (1994) 81-88.
- [77] Prieto J., Hernández A.M., Tabarés E., Loss of pseudorabies virus thymidine kinase activity due to a single base mutation and amino acid substitution, *J. Gen. Virol.* 72 (1991) 1435-1439.
- [78] Priola S.A., Stevens J.G., The 5' and 3' limits of transcription in the pseudorabies virus latency associated transcription unit, *Virology* 182 (1991) 852-856.
- [79] Quint W., Gielkens A., van Oirschot J., Berns A., Cuypers H.T., Construction and characterization of deletion mutants of pseudorabies virus: a new generation of "Live" vaccines, *J. Gen. Virol.* 68 (1987) 523-534.
- [80] Rauh I., Weiland F., Fehler F., Keil G., Mettenleiter Th.C., Pseudorabies virus mutants lacking the essential glycoprotein gII can be complemented by glycoprotein gI of bovine herpesvirus 1, *J. Virol.* 65 (1991) 621-631.
- [81] Rea T., Timmins J., Long G., Post L., Mapping and sequence of the gene for the pseudorabies virus glycoprotein which accumulates in the medium of infected cells, *J. Virol.* 54 (1985) 21-29.
- [82] Robbins A.K., Ryan J.P., Whealy M.E., Enquist L.W., The gene encoding the gIII envelope protein of pseudorabies virus vaccine strain Bartha contains a mutation affecting protein localization, *J. Virol.* 73 (1989) 250-258.
- [83] Robbins A.K., Watson R.J., Whealy M.E., Hays W.W., Enquist L.W., Characterization of a pseudorabies virus glycoprotein gene with homology to herpes simplex virus type 1 and type 2 glycoprotein C, *J. Virol.* 58 (1986) 339-347.
- [84] Robbins A.K., Dorney D.J., Wathen M.W., Whealy M.E., Gold C., Watson R.J., Holland L.E., Weed S.D., Levine M., Glorioso J.C., Enquist L.W., The pseudorabies virus gII gene is closely related to the gB glycoprotein gene of herpes simplex virus, *J. Virol.* 61 (1987) 2691-2701.
- [85] Schmidt J., Klupp B.G., Karger A., Mettenleiter Th.C., Adaptability in herpesviruses: glycoprotein D-independent infectivity of pseudorabies virus, *J. Virol.* 71 (1997) 17-24.
- [86] Schang L.M., Kutish G.F., Osorio F.A., Correlation between precolonization of trigeminal ganglia by attenuated strains of pseudorabies virus and resistance to wild-type virus latency, *J. Virol.* 68 (1994) 8470-8476.
- [87] Sodeik B., Ebersold M.W., Helenius A., Microtubule-mediated transport of incoming herpes simplex virus 1 capsids to the nucleus, *J. Cell Biol.* 136 (1997) 1007-1021.
- [88] Telford E., Watson M., McBride K., Davison A., The DNA sequence of equine herpesvirus-1, *Virology* 189 (1992) 304-316.
- [89] Ugolini G., Transneuronal tracing with alpha-herpesviruses: a review of the methodology; in: Kaplitt M., Loewy A.D. (Eds.), *Viral Vectors*, Academic Press, Inc., 1995, pp. 293-317.
- [90] van Oirschot J.T., Rziha H.J., Moonen P.J.L.M., Pol J.M.A., van Zaane D., Differentiation of serum antibodies from pigs vaccinated or infected with Aujeszky's disease virus by a competitive enzyme immunoassay, *J. Gen. Virol.* 67 (1986) 1179-1182.
- [91] van Zjil M., van de Gulden H., de Wind N., Gielkens A., Berns A., Identification of two genes in the unique short region of pseudorabies virus;

- comparison with herpes simplex virus and varicella-zoster virus, *J. Gen. Virol.* 71 (1990) 1747-1755.
- [92] van Zijl M., Wensvoort G., de Kluyver E., Hulst M., van der Gulden H., Gielkens A., Berns A., Moormann R., Live attenuated pseudorabies virus expressing envelope glycoprotein E1 of hog cholera virus protects swine against both pseudorabies and hog cholera, *J. Virol.* 65 (1991) 2761-2765.
- [93] Warner M.S., Geraghty R.J., Martinez W.M., Montgomery R.I., Whitbeck J.C., Xu R., Eisenberg R.J., Cohen G.H., Spear P.G., A cell surface protein with herpesvirus entry activity (HvE) confers susceptibility to infection by mutants of herpes simplex virus type 1, herpes simplex virus type 2, and pseudorabies virus, *Virology* 246 (1998) 179-189.
- [94] Whealy M.E., Card J.P., Meade R.P., Robbins A.K., Enquist L.W., Effect of brefeldin A on alphaherpesvirus membrane protein glycosylation and virus egress, *J. Virol.* 65 (1991) 1066-1081.
- [95] Wu S.-L., Hsiang C.-Y., Ho T.-Y., Chang T.-J., Identification, expressing, and characterization of the pseudorabies virus DNA-binding protein gene and gene product, *Virus Res.* 56 (1998) 1-9.
- [96] Yamada S., Imada T., Watanabe W., Honda Y., Nakajima-Iijima S., Shimizu Y., Sekikawa K., Nucleotide sequence and transcriptional mapping of the major capsid protein gene of pseudorabies virus, *Virology* 185 (1991) 56-66.
- [97] Zhang G., Leader D.P., The structure of the pseudorabies virus genome at the end of the inverted repeat sequences proximal to the junction with the short unique region, *J. Gen. Virol.* 71 (1990) 2433-2441.
- [98] Zhang G., Stevens R., Leader D.P., The protein kinase encoded in the short unique region of pseudorabies virus: description of the gene and identification of its product in virions and in infected cells, *J. Gen. Virol.* 71 (1990) 1757-1765.
- [99] Ziemann K., Mettenleiter Th.C., Fuchs W., Gene arrangement within the unique long genome region of infectious laryngotracheitis virus is distinct from other alphaherpesviruses, *J. Virol.* 72 (1998) 847-852.